{"id":57198,"date":"2024-07-12T12:03:43","date_gmt":"2024-07-12T12:03:43","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/07\/12\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/"},"modified":"2024-07-12T12:03:43","modified_gmt":"2024-07-12T12:03:43","slug":"adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/","title":{"rendered":"Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology\u00a0(ESMO) Congress in September"},"content":{"rendered":"
\n

SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) — Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the upcoming ESMO Congress, taking place in Barcelona, Spain, 13-17 September 2024.<\/p>\n

The poster will report results of an ongoing phase 1b\/2 trial of Adagene\u2019s masked anti-CTLA-4 SAFEbody in combination with the anti-PD-1 treatment pembrolizumab. The title is:<\/p>\n

Increased Therapeutic Index of Muzastotug (Muza, ADG126), a Masked Anti-CTLA-4 SAFEbody\u00ae<\/sup>, in Combination with Pembrolizumab (Pembro) Enables Significant Clinical Benefits and Supports Further Clinical Development in Patients with Metastatic MSS CRC<\/em><\/p>\n

The poster will be published in accordance with the ESMO embargo policy on the company\u2019s website at\u00a0www.adagene.com\/pipeline\/publications<\/a>.<\/p>\n

About\u00a0Adagene<\/strong>
Adagene Inc.\u00a0(Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.\u00a0Adagene\u00a0combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody\u00ae<\/sup>\u00a0precision masking technology in multiple approaches at the vanguard of science.<\/p>\n

Powered by its proprietary\u00a0Dynamic Precision Library\u00a0(DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene\u2019s highly differentiated pipeline features novel immunotherapy programs. The company\u2019s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment, while minimizing on-target off-tumor toxicity in healthy tissues.<\/p>\n

Adagene\u2019s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b\/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi\/multispecific T-cell engagers.<\/p>\n

For more information, please visit:\u00a0https:\/\/investor.adagene.com<\/u><\/a>.
Follow\u00a0Adagene\u00a0on\u00a0WeChat<\/u><\/a>,\u00a0LinkedIn<\/u><\/a>\u00a0and\u00a0Twitter<\/u><\/a>.<\/p>\n

SAFEbody\u00ae<\/sup>\u00a0is a registered trademark in\u00a0the United States,\u00a0China,\u00a0Australia,\u00a0Japan,\u00a0Singapore, and the\u00a0European Union.<\/p>\n

Safe Harbor Statement<\/strong>
This press release contains forward-looking statements, including statements regarding certain clinical results of ADG126, the potential implications of clinical data for patients, and Adagene\u2019s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene\u2019s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene\u2019s drug candidates; Adagene\u2019s ability to achieve commercial success for its drug candidates, if approved; Adagene\u2019s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene\u2019s reliance on third parties to conduct drug development, manufacturing and other services; Adagene\u2019s limited operating history and Adagene\u2019s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene\u2019s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene\u2019s clinical development, commercial and other operations, as well as those risks more fully discussed in the \u201cRisk Factors\u201d section in Adagene\u2019s filings with the\u00a0U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to\u00a0Adagene, and\u00a0Adagene\u00a0undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.<\/p>\n

Investor & Media Contact:<\/strong>
Ami Knoefler
Adagene
650-739-9952
ir@adagene.com<\/a><\/p>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) — Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the upcoming ESMO Congress, taking place in Barcelona, Spain, 13-17 September 2024. The poster will report results of an ongoing phase 1b\/2 […]\n","protected":false},"author":1,"featured_media":57199,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-57198","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"\nAdagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology\u00a0(ESMO) Congress in September - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology\u00a0(ESMO) Congress in September\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) — Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a company transforming the discovery\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-12T12:03:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/07\/Adagene-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology\u00a0(ESMO) Congress in September\",\"datePublished\":\"2024-07-12T12:03:43+00:00\",\"dateModified\":\"2024-07-12T12:03:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/\"},\"wordCount\":709,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/\",\"name\":\"Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology\u00a0(ESMO) Congress in September - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-07-12T12:03:43+00:00\",\"dateModified\":\"2024-07-12T12:03:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology\u00a0(ESMO) Congress in September\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology\u00a0(ESMO) Congress in September - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/","og_locale":"en_US","og_type":"article","og_title":"Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology\u00a0(ESMO) Congress in September","og_description":"SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) — Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a company transforming the discovery","og_url":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-07-12T12:03:43+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/07\/Adagene-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology\u00a0(ESMO) Congress in September","datePublished":"2024-07-12T12:03:43+00:00","dateModified":"2024-07-12T12:03:43+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/"},"wordCount":709,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/","url":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/","name":"Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology\u00a0(ESMO) Congress in September - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-07-12T12:03:43+00:00","dateModified":"2024-07-12T12:03:43+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-announces-poster-presentation-on-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-upcoming-european-society-for-medical-oncology-esmo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology\u00a0(ESMO) Congress in September"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/57198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=57198"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/57198\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/57199"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=57198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=57198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=57198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}